| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/31/2005 | US6900244 Controlling lipid, cholesterol metabolism; anticholesterol agents |
| 05/31/2005 | US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 05/31/2005 | US6900226 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/31/2005 | US6900216 Psychological disorders; antidepressants; brain diosrders; anticonvulsants |
| 05/31/2005 | US6900212 Anxiolytic agents; psychological disorders; sexual disorders; eating disorders |
| 05/31/2005 | US6900205 Antidiabetic agents |
| 05/31/2005 | US6900201 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/31/2005 | US6900197 Cobalt-porphyrin complexes and use thereof as an anti-obesity agent |
| 05/31/2005 | US6900180 Mixture of folic acid, vitamin b6 and b12 with carbohydrates, fats and proteins; infant formula; sleep disorders |
| 05/31/2005 | US6900177 Anticholesterol agents; cardiovascular disorders |
| 05/31/2005 | US6900174 Comprises mineral (chromium and/or vanadium) bound by glycoprotein matrix produced by yeast (Saccharomyces cervisiae); for inhibiting absorption of dietary starch; for obesity and other carbohydrate limited dieting |
| 05/31/2005 | US6900055 Oxygen permeable biocompatible elastomer for propagating viable tissue; tissue engineering |
| 05/31/2005 | US6900043 Phosphatases which activate map kinase pathways |
| 05/31/2005 | US6900038 eNOS mutations useful for gene therapy and therapeutic screening |
| 05/31/2005 | US6899896 Hydrogel-driven layered drug dosage form |
| 05/31/2005 | US6899883 Treatment of diabetes |
| 05/26/2005 | WO2005047455A2 Methods for the production of apolipoproteins in transgenic plants |
| 05/26/2005 | WO2005047251A1 Melanocortin receptor agonists |
| 05/26/2005 | WO2005047250A1 N-acylated-3- (benzoyl) - pyrrolidines as 11-beta-hsd1 inhibitors useful for the treatment of metabolic disorders. |
| 05/26/2005 | WO2005046689A2 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 05/26/2005 | WO2005046569A2 Pharmaceutical compositions for the treatment of sars |
| 05/26/2005 | WO2005028438A9 Novel piperidine derivative |
| 05/26/2005 | WO2005013957A3 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 05/26/2005 | WO2005000843A3 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 05/26/2005 | WO2005000318B1 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 05/26/2005 | WO2003004039A9 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases |
| 05/26/2005 | US20050113595 C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113459 Compositions for diabetes |
| 05/26/2005 | US20050113451 7-acetamidinyl derivatives |
| 05/26/2005 | US20050113440 Compounds that modulate PPAR activity and methods for their preparation |
| 05/26/2005 | US20050113435 Histamine-3 receptor ligands for diabetic conditions |
| 05/26/2005 | US20050113426 Polyhydroxylated benzene-containing compounds |
| 05/26/2005 | US20050113422 5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-2,3-dihydro-indol-1-yl}-acetic acid methyl ester or an oxazole analogous compound; side effect reduction; non-insulin dependent diabetes; hypoglycemic agents; obesity; hyperlipemia; anticholesterol agents; atherosclerosis |
| 05/26/2005 | US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 05/26/2005 | US20050113402 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 05/26/2005 | US20050113386 Treating bipolar disorder, mania, dementia, sexual dysfunction, eating disorders, fibromyalgia |
| 05/26/2005 | US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep |
| 05/26/2005 | US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors |
| 05/26/2005 | US20050113374 Benzodioxepine derivatives |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113362 Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 05/26/2005 | US20050113361 Amide derivatives as NMDA receptor antagonists |
| 05/26/2005 | US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 05/26/2005 | US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone |
| 05/26/2005 | US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders |
| 05/26/2005 | US20050113349 2-Alpha vitamin D derivatives having substituents |
| 05/26/2005 | US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries |
| 05/26/2005 | US20050113315 Such as methyl-4-(2-hydroxybenzyl)benzoate for treatment/prevention of diabetes, diabetic complications, and/or obesity; sodium glucose transport protein inhibitors |
| 05/26/2005 | US20050113314 For treating microalbuminuria, nephropathies, retinopathies, and erectile dysfunction; side effect reduction |
| 05/26/2005 | US20050113312 2-0-(-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containning compositions comprising it |
| 05/26/2005 | US20050113299 Protein a compositions and methods of use |
| 05/26/2005 | US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/26/2005 | US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies |
| 05/26/2005 | US20050112668 Determination sensitivity for development fat metabolism diosrders by comparison of gene expression levels |
| 05/26/2005 | US20050112575 Nucleic acid sequence encoding polypeptides; triggering calcium oscillation in ooctyes ; determination fertility |
| 05/26/2005 | US20050112574 Isolated nucleic acid; angiogenesis inhibitor |
| 05/26/2005 | US20050112570 Indicator for development of diabetes |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112556 Drug screening; endogenous human retrovirus; protein or peptide expressed by said retrovirus |
| 05/26/2005 | US20050112211 Micronutrient supplement |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112189 Hard capsules |
| 05/26/2005 | US20050112125 Methods of modulating lipid metabolism and storage |
| 05/26/2005 | US20050112112 Lactobacillus for treatment of eating disorders and pancreas defects; obesity; antidiabetic agents |
| 05/26/2005 | US20050112103 Genetic engineered vectors encoding human low density lipoproteins ; control sequencing, gene expressionin heptacytes; anticholesterol agents; antilipemic agents |
| 05/26/2005 | CA2546079A1 Lipometabolism improver containing pine bark extract |
| 05/26/2005 | CA2545364A1 Methods of modulating angiogenesis and cancer cell proliferation |
| 05/26/2005 | CA2545204A1 Compositions of a cholesterol biosynthesis inhibitor and a soluble fiber for the treatment of conditions associated with elevated cholesterol levels |
| 05/26/2005 | CA2545058A1 4-biarylyl-1-phenylazetidin-2-ones |
| 05/26/2005 | CA2545020A1 Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators |
| 05/26/2005 | CA2544309A1 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| 05/26/2005 | CA2544252A1 Stem cell culture medium and method of using said medium and the cells |
| 05/26/2005 | CA2544239A1 Methods for the production of apolipoproteins in transgenic plants |
| 05/26/2005 | CA2543596A1 Hdl-boosting combination therapy complexes |
| 05/26/2005 | CA2543582A1 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 05/25/2005 | EP1533619A2 Specific markers for metabolic syndrome |
| 05/25/2005 | EP1533382A1 Beta glucan-containing fat and oil compositions and novel microorganism capable of producing beta-glucan |
| 05/25/2005 | EP1533374A1 Novel peptides having camp producing activity |
| 05/25/2005 | EP1533368A1 Method of screening insulin resistance improving drug |
| 05/25/2005 | EP1533312A1 Hetero-bicyclic compounds |
| 05/25/2005 | EP1533294A1 Beta-alanine derivative and use thereof |
| 05/25/2005 | EP1533292A1 Dibenzylamine compound and medicinal use thereof |
| 05/25/2005 | EP1532979A1 Drug composition for blood sugar control |
| 05/25/2005 | EP1532446A2 G-protein coupled receptor ligands and methods |
| 05/25/2005 | EP1532242A2 Methods for preparing purified prostaglandin e synthase |
| 05/25/2005 | EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 05/25/2005 | EP1532161A2 Vectors for expression of hml-2 polypeptides |
| 05/25/2005 | EP1532153A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 05/25/2005 | EP1532150A1 Novel purine derivatives, production and use thereof as medicaments |
| 05/25/2005 | EP1532149A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| 05/25/2005 | EP1532147A1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 05/25/2005 | EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 05/25/2005 | EP1532144A1 Novel quinuclidine derivatives and their use |
| 05/25/2005 | EP1532135A1 Nf-kb inhibitors |
| 05/25/2005 | EP1532133A1 Nf-:b inhibitors |
| 05/25/2005 | EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 05/25/2005 | EP1532113A2 Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 05/25/2005 | EP1531847A2 Pharmaceutical formulation |
| 05/25/2005 | EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors |